tbuckley/cabot-search huggingface dataset:
Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018
Authors: Jeng-Sen Tseng, Chun-Ju Chiang, Kun-Chieh Chen, Zhe-Rong Zheng, Tsung-Ying Yang, Wen-Chung Lee, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Tsang-Wu Liu, Jiun-Yi Hsia, Gee-Chen Chang
Journal: JAMA Network Open (2022)

Small cell lung carcinoma (SCLC) is uncommon in individuals who have never smoked (never-smokers). The related epidemiologic factors and prognosis remain unclear.To assess the epidemiologic factors, clinical characteristics, and outcomes of SCLC in never-smokers.A retrospective cohort study was conducted using data from the national Taiwan Cancer Registry, which was inaugurated in 1979 and maintains standardized records of patients' characteristics and clinical information for all individuals with cancer. Patients with cytologically or pathologically proven lung cancer were included for analysis. The study obtained data on patients from January 1, 1996, to December 31, 2018; data analysis was conducted from January 1, 1996, to December 31, 2019.Clinical characteristics and outcomes of smokers and never-smokers with SCLC.Clinical characteristics for comparison included age at diagnosis, sex, performance status, tumor stage, and treatment. The main outcome parameter was overall survival of patients with SCLC from 2011 to 2018.From 1996 to 2018, a total of 225 788 patients had diagnosed lung cancer; 141 654 patients (62.7%) were men; mean (SD) age was 67.55 (12.58) years. The numbers of both patients with newly diagnosed lung cancer and those with SCLC increased until 2009 by 111.5% for lung cancer and 118.5% for SCLC. Thereafter, lung cancer cases grew in number, but SCLC cases did not; hence, the percentage of patients with SCLC decreased from 9.3% in 2009 to 6.3% in 2018. From 2011 to 2018, the percentage of never-smokers increased significantly among all patients with lung cancers (from 49.9% in 2011 to 60.2% in 2018) and among those with lung adenocarcinomas (from 64.1% in 2011 to 70.9% in 2018) (both P < .001). However, the percentage of never-smokers appeared to vary little in the SCLC population: 15.5% in 2011 and 16.1% in 2018 (P = .28). The median overall survival was significantly longer in patients with adenocarcinoma vs SCLC (adjusted hazard ratio, 0.32; 95% CI, 0.31-0.33; P < .001). Compared with smokers with SCLC, never-smokers with SCLC tended to include more older patients (age ≥70 years: 492 [57.3%] vs 2242 [44.8%]), more women (274 [31.9%] vs 322 [6.4%]), more individuals with a poor performance status (Eastern Cooperative Oncology Group performance status ≥2: 284 [33.1%] vs 1261 [25.2%]) and stage IV cancer (660 [76.9%] vs 3590 [71.8%]), and more patients without treatment (203 [23.7%] vs 626 [12.5%]). Furthermore, never-smokers, particularly men, experienced a shorter survival rate (adjusted hazard ratio, 1.10; 95% CI, 1.00-1.20; P = .04) compared with the other groups.The findings of this cohort study suggest that the decrease in the percentage of patients with SCLC was associated with increased lung cancers of other histologic types, with no substantial decrease in the number of those with SCLC.
RISK FACTORS OF ARTERIAL THROMBOEMBOLISM IN HOSPITALIZED COVID-19 PATIENTS: A MULTICENTER COHORT STUDY
Authors: Yi Lee, Qasim Jehangir, Chun-Hui Lin, Pin Li, Geetha Krishnamoorthy, Anupam Sule, Dinesh Apala, Abdul R. Halabi, Kiritkumar Patel, Dee Dee Wang, Laila Poisson, Girish B. Nair
Journal: Journal of the American College of Cardiology (2022)
COVID-INDUCED LEFT VENTRICULAR ANEURYSM WITH SYSTEMIC EMBOLI SHOWERS
Authors: Thanh Dinh Hoang, William Sanchez-Garcia, Taylor Sharpe, Bradley Casey, Amudhan Jyothidasan, Renaldo Neeley, Alejandro Chapa-Rodriguez, Manoj Bhandari
Journal: Journal of the American College of Cardiology (2022)
<i>JAMA Internal Medicine</i>—Year in Review, 2021
Authors: Rita F. Redberg
Journal: JAMA Internal Medicine (2022)

We start another year with the continuing COVID-19 pandemic and much coverage in the news and medical journals, as well as progress.Thankfully, we now have widespread vaccinations and effective public health measures.The latest highly contagious Omicron variant, which has slowed the highly anticipated recovery, finally appears to be subsiding.We remain optimistic that we will learn how best to live with this "new normal," 1 and we can get back to the hard work of promoting high-value health care that is accessible to all.This year began with a courageous and groundbreaking draft decision by the US Centers for Medicare & Medicaid Services (CMS) to cover a controversial treatment for Alzheimer disease, while actively leading the generation of much needed clinical trial data in partnership with the National Institutes of Health.This innovative framework is known as coverage with evidence development.The drug in question, aducanumab, received accelerated approval in a controversial and fraught decision by the US Food and Drug Administration and led to many questions (and ongoing congressional investigation), including that of a threat to the financial solvency of Medicare.
Single-cell transcriptomes in the heart: when every epigenome counts
Authors: Tatiana Gromova, Natalie D Gehred, Thomas M Vondriska
Journal: Cardiovascular Research (2022)

The response of an organ to stimuli emerges from the actions of individual cells. Recent cardiac single-cell RNA-sequencing studies of development, injury, and reprogramming have uncovered heterogeneous populations even among previously well-defined cell types, raising questions about what level of experimental resolution corresponds to disease-relevant, tissue-level phenotypes. In this review, we explore the biological meaning behind this cellular heterogeneity by undertaking an exhaustive analysis of single-cell transcriptomics in the heart (including a comprehensive, annotated compendium of studies published to date) and evaluating new models for the cardiac function that have emerged from these studies (including discussion and schematics that depict new hypotheses in the field). We evaluate the evidence to support the biological actions of newly identified cell populations and debate questions related to the role of cell-to-cell variability in development and disease. Finally, we present emerging epigenomic approaches that, when combined with single-cell RNA-sequencing, can resolve basic mechanisms of gene regulation and variability in cell phenotype.
SHORT-TERM OUTCOMES FOLLOWING LEFT ATRIAL APPENDAGE CLOSURE IN THE VERY ELDERLY: A POPULATION-BASED ANALYSIS
Authors: Medhat Farwati, Mustapha Amin, Toshiaki Isogai, Anas M. Saad, Abdelrahman Abushouk, Amar Krishnaswamy, Oussama M. Wazni, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2022)
Acoustic Bioprinting of Patient‐Derived Organoids for Predicting Cancer Therapy Responses
Authors: Hui Chen, Zhuhao Wu, Zhiyi Gong, Yu Xia, Juan Li, Liang Du, Yuanzheng Zhang, Xiangyang Gao, Zhou Fan, Hang Hu, Qun Qian, Zhao Ding, Shishang Guo
Journal: Advanced Healthcare Materials (2022)

Cancer models, which are biologically representative of patient tumors, can predict the treatment responses and help determine the most appropriate cancer treatment for individual patients. Here, a point-of-care testing system called acoustically bioprinted patient-derived microtissues (PDMs) that can model cancer invasion and predict treatment response in individual patients with colorectal cancer (CRC), is reported. The PDMs are composed of patient-derived colorectal tumors and healthy organoids which can be precisely arranged by acoustic bioprinting approach for recapulating primary tissue's architecture. Particularly, these tumor organoids can be efficiently generated and can apprehend histological, genomic, and phenotypical characteristics of primary tumors. Consequently, these PDMs allow physiologically relevant in vitro drug (5-fluorouracil) screens, thus predicting the paired patient's responses to chemotherapy. A correlation between organoid invasion speed and normalized spreading speed of the paired patients is further established. It provides a quantitative indicator to help doctors make better decisions on ultimate anus-preserving operation for extremely low CRC patients. Thus, by combing acoustic bioprinting and organoid cultures, this method may open an avenue to establish complex 3D tissue models for precision and personalized medicine.
Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort
Authors: James T. England, Caroline J. McNamara, James A. Kennedy, Jose-Mario Capo-Chichi, Jingyue Huang, Andrea Arruda, Taylor Nye, Verna Cheung, Jaime O. Claudio, Dawn Maze, Hassan Sibai, Anne Tierens, Hubert Tsui, Aniket Bankar, Wei Xu, Tracy Stockley, Vikas Gupta
Journal: Leukemia (2022)

Myelofibrosis (MF) is an acquired clonal hematopoietic stem cell disorder associated with debilitating constitutional symptoms, extramedullary hematopoiesis resulting in splenomegaly, and a propensity to transform to a blast phase/acute myeloid leukemia (AML).The discovery of JAK inhibitors (JAKi) has been pivotal in the treatment of symptomatic MF by reducing spleen size, and alleviating cytokine-related symptom burden [1].Despite this, up to 50% of MF patients discontinue JAKi by 2-3 years and only one quarter of patients remain on treatment at 5 years [2,3].Prospective trials of JAKi therapy provide little information after patients discontinue therapy and safety specific follow up is completed.Although survival following ruxolitinib cessation is poor, in the range 13-16 months, the clinical course and reasons for JAKi failure in MF patients are not well characterized [4][5][6][7].Criteria for JAKi failure are variably defined in retrospective studies and second-line JAKi therapy trials [8][9][10].JAKi therapy may fail for a variety of reasons including sub-optimal/loss of spleen response, severe cytopenias, progression to an accelerated or blast phase (AP/BP) of disease, secondary malignancies other than AML, recurrent severe infections, or other non-hematological toxicities.Recognition of patterns of failure is important to accurately characterize, and plan treatment strategies in these patients.We conducted a retrospective study analyzing a molecularly annotated, mature dataset of MF patients treated with JAKi followed in a prospective MPN registry (NCT02760238) at Princess Margaret Cancer Centre.We evaluated the impact of baseline clinical and molecular factors on clinical outcomes and therapy failure.We characterized different patterns of JAKi failure according to consensus criteria of the Canadian MPN Group (Supp.Table S1) [11] and its impact on survival.In a sub-set of patients with paired samples we evaluated the impact of clonal evolution on outcomes following JAKi failure.Cohort selection, study definitions, molecular, and statistical analysis are summarized in Appendix.
SARS-CoV-2 Placentitis and Intraparenchymal Thrombohematomas Among COVID-19 Infections in Pregnancy
Authors: Anh Huynh, Jennifer K. Sehn, Ilona Telefus Goldfarb, Jaclyn Watkins, Vanda Torous, Amy Heerema-McKenney, Drucilla J. Roberts
Journal: JAMA Network Open (2022)

a Includes 1 placenta from dichorionic-diamniotic twins.b This category includes cases with severe complications such as respiratory distress requiring intubation, early neonatal death, or intraventricular hemorrhage.c This category may include cases with complications of prematurity not previously specified as severe.d Mild symptoms include cough, fever, myalgias, chills, loss of taste and smell, nausea and vomiting, and diarrhea.Severe symptoms include pneumonia and respiratory distress requiring intensive care unit admission and/or intubation.e There may be multiple indications for each delivery.
INFLAMMATION AND VASCULAR REMODELING IN COVID-19 HEARTS
Authors: Christopher Werlein, Maximilian Ackermann, Harshit R. Shah, Helge Stark, Florian Laenger, Tim Salditt, Tobias Welte, Johann Bauersachs, Axel Haverich, Saskia von Stillfried, Mark Kuehnel, Roman Buelow, Peter Boor, Stephen M. Black, Steven J. Mentzer, Danny Jonigk
Journal: Journal of the American College of Cardiology (2022)
DEEP LEARNING ANALYSIS USING CARDIOVASCULAR MAGNETIC RESONANCE IMAGING FOR RISK PREDICTION IN CARDIAC AMYLOIDOSIS
Authors: Joshua Cockrum, David Chen, Makiya Nakashima, Joseph Mauch, Mazen A. Hanna, Kaia Kanj, Basnet Ramesh, Mitchel Benovoy, Samir R. Kapadia, Lars G. Svensson, Brian P. Griffin, Scott D. Flamm, Richard A. Grimm, Wai Hong Wilson Tang, Deborah Kwon
Journal: Journal of the American College of Cardiology (2022)
Droplet-microfluidics-assisted sequencing of HIV proviruses and their integration sites in cells from people on antiretroviral therapy
Authors: Chen Sun, Leqian Liu, Liliana Pérez, Xiangpeng Li, Yifan Liu, Peng Xu, Eli A. Boritz, James I. Mullins, Adam R. Abate
Journal: Nature Biomedical Engineering (2022)
OUTCOMES OF PATIENTS WITH PULMONARY EMBOLISM WITH HISTORY OF COVID-19 ARE AS POOR AS PATIENTS WITH PULMONARY EMBOLISM WITH SEVERE COVID-19
Authors: Timothy D. Ho, Shonit Nandakumar, Lily Zhong, Magnus To, Hyunju Heineke, Napatkamon Ayutyanont, Scott Kubomoto, Sandeep Sangodkar, Mimi S. Biswas
Journal: Journal of the American College of Cardiology (2022)
REGIONAL HETEROGENEITY OF EXERCISE-INDUCED CITED4 EXPRESSION IS SPATIALLY LINKED WITH CARDIAC MICROSTRUCTURAL REMODELING CHARACTERIZED BY DIFFUSION TENSOR CARDIAC MAGNETIC RESONANCE
Authors: Robert Eder, Maaike Van Den Boomen, Salva Yurista, Yaiel Rodriguez-Aviles, Mohammad Rashedul Islam, Yin-Ching I. Chen, Lena Trager, Jaume Coll-Font, Leo Cheng, Haobo Li, Anthony Rosenzweig, Christiane Wrann, Christopher Nguyen
Journal: Journal of the American College of Cardiology (2022)
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions
Authors: Keertan Dheda, Tahlia Perumal, Harry Moultrie, Rubeshan Perumal, Aliasgar Esmail, Alex J Scott, Zarir Udwadia, Kwok Chiu Chang, Jonathan Peter, Anil Pooran, Arne von Delft, Dalene von Delft, Neil Martinson, Marian Loveday, Salome Charalambous, Elizabeth Kachingwe, Waasila Jassat, Cheryl Cohen, Stefano Tempia, Kevin Fennelly, Madhukar Pai
Journal: The Lancet Respiratory Medicine (2022)
68Ga-DOTATATE and 68Ga-PSMA Uptake in Granulomatous Prostatitis
Authors: Dan Ruan, Long Sun
Journal: Clinical Nuclear Medicine (2022)

Abstract 68 Ga-PSMA and 68 Ga-DOTATATE PET/CT have shown promising performance in diagnosing prostate cancer and neuroendocrine tumors, but there are also pitfalls. We report a case of a 78-year-old man with prostate lesions showing intense uptake of 18 FDG, 68 Ga-PSMA, and 68 Ga-DOTATATE simultaneously, with heterogeneous enhancement on contrast-enhanced CT and abnormal signal changes on PET/MRI. It was finally diagnosed as granulomatous prostatitis. This case suggests that granulomatous prostatitis has a high uptake of various imaging agents and is easily misdiagnosed as prostate cancer.
CARDIAC EVENTS AFTER ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL (IDECABTAGENE VICLEUCEL) FOR MULTIPLE MYELOMA
Authors: Dae Hyun Lee, Sanjay Amrith Chandrasekhar, Michael Jain, Doris Hansen, Ciara Freeman, Melissa Alsina, Rachid Baz, Omar Castaneda Puglianini, Hien Liu, Brandon Blue, Marco L. Davila, Rawan Faramand, Abhishek Kumar, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Frederick Locke, Guilherme Henrique Oliveira, Mohammed Alomar
Journal: Journal of the American College of Cardiology (2022)
MILD RENAL DYSFUNCTION IS ASSOCIATED WITH INCIDENT ATRIAL FIBRILLATION AMONG HEALTHY ADULTS
Authors: Shmuel Tiosano, Alexander Fardman, Alon Kaplan, Maia Kalstein, Yonatan Moshkovits, Shlomo Segev, Pazit Beckerman, Amit Segev, Ehud Grossman, Elad Maor
Journal: Journal of the American College of Cardiology (2022)
ARRHYTHMIA-INDUCED CARDIOMYOPATHY DUE TO PARAHISIAN PREMATURE VENTRICULAR COMPLEXES WITH SUCCESSFUL CATHETER ABLATION
Authors: Jose Ramon Benitez, Juan Alan Fuentes Mendoza, Elizabeth Gomez Ureña, Cesar Gerardo Galvan Vargas, Rafael Ignacio Aguilar Reynoso, Luis Enrique Berumen Dominguez, Marcos Alarcon, Oscar G Jimenez Cabrera, Jose Antonio Citalan Jimenez
Journal: Journal of the American College of Cardiology (2022)
HEART FAILURE AS THE CANCER OF THE HEART: THE PROMISING PROGNOSTIC TOOL OF TNMLIKE CLASSIFICATION
Authors: Andrea D’Amato, Paolo Severino, Marco Valerio Mariani, Silvia Prosperi, Danilo Alunni Fegatelli, Mariateresa Pucci, Danilo Angotti, Bettina Costi, Enrico Cerrato, Annarita Vestri, Alberto Palazzuoli, Paul N. Casale, Paul J. Mather, Massimo Mancone, Francesco Fedele
Journal: Journal of the American College of Cardiology (2022)
A UNIQUE PRESENTATION OF EXERCISE INDUCED CORONARY VASOSPASM
Authors: Nicholas Taklalsingh, Jeremy Jaehwan Oh, Ganesh Keshav Thirunavukkarasu, Seyed M. Zaidi, Dale Railwah, Jonathan D. Marmur, Alan Feit, Louis F. Salciccioli
Journal: Journal of the American College of Cardiology (2022)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Authors: Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, Larry A. Allen, Joni J. Byun, Monica M. Colvin, Anita Deswal, Mark H. Drazner, Shannon M. Dunlay, Linda R. Evers, James C. Fang, Savitri E. Fedson, Gregg C. Fonarow, Salim S. Hayek, Adrian F. Hernandez, Prateeti Khazanie, Michelle M. Kittleson, Christopher S. Lee, Mark S. Link, Carmelo A. Milano, Lorraine C. Nnacheta, Alexander T. Sandhu, Lynne Warner Stevenson, Orly Vardeny, Amanda R. Vest, Clyde W. Yancy
Journal: Journal of the American College of Cardiology (2022)
TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members
Authors: Rachel Delahunty, Linh Nguyen, Stuart Craig, Belinda Creighton, Dinuka Ariyaratne, Dale W. Garsed, Elizabeth Christie, Sian Fereday, Lesley Andrews, Alexandra Lewis, Sharne Limb, Ahwan Pandey, Joy Hendley, Nadia Traficante, Natalia Carvajal, Amanda B. Spurdle, Bryony Thompson, Michael T. Parsons, Victoria Beshay, Mila Volcheck, Timothy Semple, Richard Lupat, Kenneth Doig, Jiaan Yu, Xiao Qing Chen, Anna Marsh, Christopher Love, Sanela Bilic, Maria Beilin, Cassandra B. Nichols, Christina Greer, Yeh Chen Lee, Susan Gerty, Lynette Gill, Emma Newton, Julie Howard, Rachel Williams, Christie Norris, Andrew N. Stephens, Erin Tutty, Courtney Smyth, Shona O'Connell, Thomas Jobling, Colin J.R. Stewart, Adeline Tan, Stephen B. Fox, Nicholas Pachter, Jason Li, Jason Ellul, Gisela Mir Arnau, Mary-Anne Young, Louisa Gordon, Laura Forrest, Marion Harris, Karen Livingstone, Jane Hill, Georgia Chenevix-Trench, Paul A. Cohen, Penelope M. Webb, Michael Friedlander, Paul James, David Bowtell, Kathryn Alsop
Journal: Journal of Clinical Oncology (2022)

Tubo-ovarian cancer (TOC) is a sentinel cancer for BRCA1 and BRCA2 pathogenic variants (PVs). Identification of a PV in the first member of a family at increased genetic risk (the proband) provides opportunities for cancer prevention in other at-risk family members. Although Australian testing rates are now high, PVs in patients with TOC whose diagnosis predated revised testing guidelines might have been missed. We assessed the feasibility of detecting PVs in this population to enable genetic risk reduction in relatives.In this pilot study, deceased probands were ascertained from research cohort studies, identification by a relative, and gynecologic oncology clinics. DNA was extracted from archival tissue or stored blood for panel sequencing of 10 risk-associated genes. Testing of deceased probands ascertained through clinic records was performed with a consent waiver.We identified 85 PVs in 84 of 787 (11%) probands. Familial contacts of 39 of 60 (65%) deceased probands with an identified recipient (60 of 84; 71%) have received a written notification of results, with follow-up verbal contact made in 85% (33 of 39). A minority of families (n = 4) were already aware of the PV. For many (29 of 33; 88%), the genetic result provided new information and referral to a genetic service was accepted in most cases (66%; 19 of 29). Those who declined referral (4 of 29) were all male next of kin whose family member had died more than 10 years before.We overcame ethical and logistic challenges to demonstrate that retrospective genetic testing to identify PVs in previously untested deceased probands with TOC is feasible. Understanding reasons for a family member's decision to accept or decline a referral will be important for guiding future TRACEBACK projects.
Colorectal Cancer Surveillance With Circulating Tumor DNA Assay
Authors: Alan P. Venook
Journal: JAMA Network Open (2022)

Marwan Fakih, MD; Jaideep Sandhu, MBBS, MPH; Chongkai Wang, MD, MS; Jae Kim, MD; Yi-Jen Chen, MD, PhD; Lily Lai, MD; Kurt Melstrom, MD; Andreas Kaiser, MD
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML
Authors: H. Moses Murdock, Haesook T. Kim, Nathan Denlinger, Pankit Vachhani, Bryan Hambley, Bryan S. Manning, Shannon Gier, Christina Cho, Harrison K. Tsai, Shannon McCurdy, Vincent T. Ho, John Koreth, Robert J. Soiffer, Jerome Ritz, Martin P. Carroll, Sumithira Vasu, Miguel-Angel Perales, Eunice S. Wang, Lukasz P. Gondek, Steven Devine, Edwin P. Alyea, R. Coleman Lindsley, Christopher J. Gibson
Journal: Blood (2022)
EPR22-111: Outcomes and Utilization of Adjuvant Chemotherapy With and Without an Anthracycline in Node-Positive, Triple-Negative Breast Cancer: Analysis of SEER-Medicare Data
Authors: Stephanie Lakritz, Anna Schreiber, Elizabeth Molina, Elisabeth Meyer, Cathy J Bradley, Jennifer R Diamond
Journal: Journal of the National Comprehensive Cancer Network (2022)

"EPR22-111: Outcomes and Utilization of Adjuvant Chemotherapy With and Without an Anthracycline in Node-Positive, Triple-Negative Breast Cancer: Analysis of SEER-Medicare Data" published on 31 Mar 2022 by National Comprehensive Cancer Network.
ULTRASOUND-ENHANCED THERAPEUTIC VASCULAR DELIVERY
Authors: Melvin Klegerman, Melanie Moody, Tao Peng, Susan T. Laing, Shaoling Huang, Vijay Govindarajan, Hyunggun Kim, Kevin Haworth, Curtis Gensler, Christy K. Holland, David D. McPherson, Patrick Kee
Journal: Journal of the American College of Cardiology (2022)
SPONTANEOUS CORONARY ARTERY DISSECTION PRESENTING AS ACUTE ST SEGMENT ELEVATION INFERIOR WALL MYOCARDIAL INFARCTION IN PATIENT WITH CORONAVIRUS DISEASE 2019. ARE PERICYTES THE MISSING LINK?
Authors: Nisha Ali, Muhammad Saad, Hitesh Gurjar, Rishi Shrivastava, Timothy J. Vittorio, Nassim Krim
Journal: Journal of the American College of Cardiology (2022)
18P Baseline and dynamic changes in haemoglobin levels predict treatment response and disease progression in metastatic renal cell carcinoma
Authors: Y-H. Yang, A. Meerveld-Eggink, A. Bex, F. Jackson-Spence, K.S. Rallis, P.R. Brian, J. Choy, C.C. Sng, P. Adeniran, J. Amin, S. Galope, N. Anderson, S. Fernandezgomez, T.B. Powles, B.E. Szabados
Journal: Annals of Oncology (2022)